Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genmab has initiated Phase III study of single agent Ofatumumab compared to single agent Rituximab in patients with follicular non-Hodgkin's lymphoma (NHL) that has relapsed at least 6 months after completion of treatment with a rituximab-containing regimen to which they responded.
Subscribe to our email newsletter
Ofatumumab is a novel human monoclonal antibody. It targets a part of the CD20 molecule on B-cells encompassing an epitope on the small and large loops.
In the open-label study, approximately 516 patients are expected to be randomised to receive Ofatumumab (1000mg) or Rituximab (375mg/m2) by intravenous infusion for four weekly doses.
Additionally, patients who have stable or responsive disease will then receive single infusions of Ofatumumab or Rituximab every two months for four additional doses for a total of eight doses over nine months.
Genmab said that the primary endpoint of the study is progression free survival.
Ofatumumab is not approved in any country for indolent B-cell non-Hodgkin’s lymphoma (B-NHL).